Organizations Filed Purposes:
CARE PROMOTES AWARENESS ABOUT CANCER TREATMENT AND PREVENTION THROUGH EDUCATIONAL FORUMS AND SEMINARS AND RAISES MONEY TO PROVIDE SEED-FUNDING TO FUND INNOVATIVE NEW CANCER RESEARCH PROJECTS AND CLINICAL TRIALS IN THE PHOENIX AREA.
CARE PROVIDED SEED-FUNDING TO START A NEW PROJECT CALLED INTERCEPT TO STUDY SPORADIC AND INHERITED CANCER. INTERCEPT WILL ENABLE MAYO CLINIC TO FOCUS ON THE UNDER-STUDIED COHORT OF PATIENTS WHOSE CANCER IS NOT EXPLAINED BY FAMILIAL OCCURRENCE BUT WHOSE INCIDENCE OF GENE MUTATION IN THE GENERAL POPULATION IS THOUGHT TO BE AS HIGH AS 20%. EXPLORATION OF THE RISKS OF SPORADIC CANCER ARE NOT CAPTURED BY CURRENT TREATMENT GUIDELINES. THE KEY OPPORTUNITIES OF THIS PROGRAM ARE TO: 1) IDENTIFY THE IMPACT OF INHERITED MUTATIONS ON CANCER BEHAVIOR, 2) UNDERSTAND THE IMPACT OF INHERITED MUTATIONS ON CANCER MONITORING, 3) EXPLORE PERSONALIZED STRATEGIES FOR CANCER TREATMENT. INTERCEPT TESTING WILL DETERMINE WHETHER A PATIENT HAS A SPORADIC OR INHERITED FORM OF CANCER, A CRITICAL DISTINCTION AS IT WOULD DETERMINE TREATMENT DECISIONS FOR INDIVIDUAL PATIENTS. THIS UNIQUE PILOT PROJECT WILL OFFER GENETIC TESTING, AT NO COST, TO PATIENT RELATIVES TO HELP INFORM THEM OF THEIR GENETIC CANCER RISK AS WELL.
CELLULAR THERAPY RESEARCH PROGRAM: PROGRAM WILL FOCUS ON NOVEL TREATMENTS THAT INVOLVE TRANSPLANTING HUMAN CELLS TO REPLACE OR REPAIR DAMAGED CELLS, SIMILAR TO NOW-COMMON CELL THERAPIES SUCH AS BLOOD TRANSFUSIONS AND BONE MARROW TRANSPLANTS. IT WOULD LEVERAGE HHRI'S COLLABORATIONS WITH TGEN AND CITY OF HOPE AND WILL EXTEND ITS STRONG ONCOLOGY WORK IN IMMUNOTHERAPY AND SOLID TUMORS (E.G. PANCREATIC AND BREAST). THE NEW PROGRAM WOULD INCLUDE INVESTIGATION OF AN EMERGING APPROACH CALLED ADOPTIVE CELL TRANSFER (ACT), DRAWING ON ADVANCEMENTS IN IMMUNOTHERAPY, BY COLLECTING AND USING PATENTS' OWN IMMUNE CELLS (PERSONALIZED VACCINES). 1) INTITIAL FOCUS WILL BE ON HIGHLY PROMISING TYPE OF ACT CALLED CHIMERIC ANTIGEN RECEPTORS (CAR) T-CELL THERAPY, USING A PATIENT'S OWN RE-ENGINEERED T CELLS TO FIND & KILL CANCER CELLS. 2) INITIAL EMPHASIS WILL BE ON BLOOD CANCERS (E.G. MULTIPLE MYELOMA & LEUKEMIA), BUILDING ON HONORHEALTH'S STRONG BONE MARROW TRANSPLANT PROGRAM FOR BLOOD CANCERS.
A PART OF CARE'S MISSION INCLUDES PROVIDING EDUCATIONAL AND INFORMATIONAL ACTIVITIES FOR DESERT MOUNTAIN MEMBERS. IN THE ONGOING SEMINAR SERIES "LIVE LONG & PROSPER", WE FOCUS ON THE LATEST TRENDS IN CANCER RESEARCH, TREATMENT, PREVENTION AND WELLNESS STRATEGIES. WE HOST SEMINARS AND PRESENTATIONS WITH RESEARCHERS, PHYSICIANS AND EXPERTS FROM HONORHEALTH AND MAYO CLINIC TO ADDRESS A WIDE VARIETY OF TOPICS FOR MULTIPLE AUDIENCES AT THE DESERT MOUNTAIN COMMUNITY. IN ADDITION, THE RESEARCH DOCTORS FROM HONORHEALTH & MAYO DISCUSS THE PROJECTS CARE IS FUNDING, PROGRESS BEING MADE AND NEW DIRECTIONS FOR FURTHER OR NEW RESEARCH.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Louise Zirretta | DIRECTOR | 5 | $0 |
| Suzanne Paetzer | SECRETARY & | 20 | $0 |
| Sheree Bauer | DIRECTOR | 2 | $0 |
| Wayne Mailloux | DIRECTOR | 5 | $0 |
| Jean Kennedy | DIRECTOR | 5 | $0 |
| Steve Mcmurray | DIRECTOR | 2 | $0 |
| Syliva Owens | DIRECTOR | 2 | $0 |
| Diane Hurter | DIRECTOR | 5 | $0 |
| Sandra Miller-Forman | TREASURER | 20 | $0 |
| Jill Porcellato | CHAIRMAN | 25 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202031619349301353_public.xml